



This is a repository copy of *Whole-genome sequencing of a sporadic primary immunodeficiency cohort*.

White Rose Research Online URL for this paper:
<https://eprints.whiterose.ac.uk/161754/>

Version: Accepted Version

Article:

Thaventhiran, JED, Lango Allen, H, Burren, OS et al. (56 more authors) (2020) Whole-genome sequencing of a sporadic primary immunodeficiency cohort. *Nature*, 583. pp. 90-95. ISSN 0028-0836

<https://doi.org/10.1038/s41586-020-2265-1>

This is a post-peer-review, pre-copyedit version of an article published in *Nature*. The final authenticated version is available online at: <http://dx.doi.org/10.1038/s41586-020-2265-1>

Reuse

Items deposited in White Rose Research Online are protected by copyright, with all rights reserved unless indicated otherwise. They may be downloaded and/or printed for private study, or other acts as permitted by national copyright laws. The publisher or other rights holders may allow further reproduction and re-use of the full text version. This is indicated by the licence information on the White Rose Research Online record for the item.

Takedown

If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request.



eprints@whiterose.ac.uk
<https://eprints.whiterose.ac.uk/>

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56

Whole genome sequencing of a sporadic primary immunodeficiency cohort

James E. D. Thaventhiran^{1,2,3,41}, Hana Lango Allen^{4,5,6,7,41}, Oliver S. Burren^{1,2,41}, William Rae^{1,2,41}, Daniel Greene^{4,6,8,42}, Emily Staples^{2,42}, Zinan Zhang^{1,2,9,42}, James H. R. Farmery^{10,42}, Ilenia Simeoni^{4,6}, Elizabeth Rivers^{11,12}, Jesmeen Maimaris^{11,12}, Christopher J Penkett^{4,5,6}, Jonathan Stephens^{4,5,6}, Sri V.V. Deevi^{4,5,6}, Alba Sanchis-Juan^{4,5,6}, Nicholas S Gleadall^{4,5,6}, Moira J. Thomas¹³, Ravishankar B. Sargur^{14,15}, Pavels Gordins¹⁶, Helen E. Baxendale^{1,17}, Matthew Brown^{4,5,6}, Paul Tuijnenburg¹⁸, Austen Worth^{11,12}, Steven Hanson^{19,20}, Rachel Linger^{4,5,6}, Matthew S. Buckland^{19,20}, Paula J. Rayner-Matthews^{4,5,6}, Kimberly C. Gilmour^{11,12}, Crina Samarghitean^{4,5,6}, Suranjith L. Seneviratne^{19,20}, David M. Sansom^{19,20}, Andy G. Lynch^{10,21}, Karyn Megy^{4,5,6}, Eva Ellinghaus²², David Ellinghaus^{23,24}, Silje F. Jorgensen^{25,26}, Tom H Karlsen²², Kathleen E. Stirrups^{4,5,6}, Antony J. Cutler²⁷, Dinakantha S. Kumararatne^{2,28}, Anita Chandra^{1,2,28}, J. David M. Edgar²⁹, Archana Herwadkar³⁰, Nichola Cooper³¹, Sofia Grigoriadou³², Aarnoud Huissoon³³, Sarah Goddard³⁴, Stephen Jolles³⁵, Catharina Schuetz³⁶, Felix Boschann³⁷, NBR-RD PID Consortium, NIHR BioResource⁵, Paul A. Lyons^{1,2}, Matthew E. Hurles³⁸, Sinisa Savic^{39,40}, Siobhan O. Burns^{19,20}, Taco W. Kuijpers^{18,45}, Ernest Turro^{4,5,6,8,43}, Willem H. Ouwehand^{3,4,5,39,43}, Adrian J. Thrasher^{8,9,43}, Kenneth G. C. Smith^{1,2}

1. Cambridge Institute of Therapeutic Immunology and Infectious Disease, Jeffrey Cheah Biomedical Centre, Cambridge Biomedical Campus, Cambridge, UK.
2. Department of Medicine, University of Cambridge School of Clinical Medicine, Cambridge Biomedical Campus, Cambridge, UK.
3. Medical Research Council Toxicology Unit, School of Biological Sciences, University of Cambridge, Cambridge, UK.
4. Department of Haematology, University of Cambridge School of Clinical Medicine, Cambridge Biomedical Campus, Cambridge, UK.
5. NHS Blood and Transplant, Cambridge Biomedical Campus, Cambridge, UK.
6. NIHR BioResource, Cambridge University Hospitals, Cambridge Biomedical Campus, Cambridge, UK.
7. Current address: Medical Research Council Epidemiology Unit, University of Cambridge School of Clinical Medicine, Cambridge Biomedical Campus, Cambridge, UK.
8. Medical Research Council Biostatistics Unit, Cambridge Biomedical Campus, Cambridge, UK.
9. Molecular Development of the Immune System Section, Laboratory of Immune System Biology and Clinical Genomics Program, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
10. Cancer Research UK Cambridge Institute, University of Cambridge, Li Ka Shing Centre, Robinson Way, Cambridge, UK.
11. UCL Great Ormond Street Institute of Child Health, London, UK.
12. Great Ormond Street Hospital for Children NHS Foundation Trust, London, UK.
13. Department of Immunology, Queen Elizabeth University Hospital, Glasgow, UK.
14. Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK.
15. Department of Infection Immunity and Cardiovascular Disease, University of Sheffield, Sheffield, UK.
16. East Yorkshire Regional Adult Immunology and Allergy Unit, Hull Royal Infirmary, Hull and East Yorkshire Hospitals NHS Trust, Hull, UK
17. Royal Papworth Hospital NHS Foundation Trust, Cambridge, UK.
18. Department of Pediatric Immunology, Rheumatology and Infectious Diseases, Emma Children's Hospital & The Department of Experimental Immunology, Amsterdam University Medical Center (AMC), University of Amsterdam, Amsterdam, The Netherlands.
19. Institute of Immunity and Transplantation, University College London, London, UK.
20. Department of Immunology, Royal Free London NHS Foundation Trust, London, UK.
21. School of Mathematics and Statistics/School of Medicine, University of St Andrews, St Andrews, UK.
22. K.G. Jebsen Inflammation Research Centre, Institute of Clinical Medicine, University of Oslo, Oslo University Hospital, Rikshospitalet, Oslo, Norway.
23. Department of Transplantation, Institute of Clinical Medicine, University of Oslo, Oslo University Hospital, Rikshospitalet, Oslo, Norway.
24. Institute of Clinical Molecular Biology, Christian Albrechts University of Kiel, Kiel, Germany.
25. Section of Clinical Immunology and Infectious Diseases, Department of Rheumatology, Dermatology and Infectious Diseases, Oslo University Hospital, Rikshospitalet, Norway.
26. Research Institute of Internal Medicine, Division of Surgery, Inflammatory Diseases and Transplantation, Oslo University Hospital, Rikshospitalet, Norway.

- 57 27. JDRC/Wellcome Diabetes and Inflammation Laboratory, Wellcome Centre for Human Genetics, Nuffield Department of
58 Medicine, NIHR Oxford Biomedical Research Centre, University of Oxford, Oxford, UK.
59 28. Department of Clinical Biochemistry and Immunology, Cambridge University Hospitals, Cambridge Biomedical Campus,
60 Cambridge, UK.
61 29. St James's Hospital & Trinity College Dublin, Ireland.
62 30. Salford Royal NHS Foundation Trust, Salford, UK.
63 31. Department of Medicine, Imperial College London, London, UK.
64 32. Barts Health NHS Foundation Trust, London, UK.
65 33. West Midlands Immunodeficiency Centre, University Hospitals Birmingham, Birmingham, UK.
66 34. University Hospitals of North Midlands NHS Trust, Stoke-on-Trent, UK.
67 35. Immunodeficiency Centre for Wales, University Hospital of Wales, Cardiff, UK.
68 36. Department of Pediatric Immunology, University Hospital Carl Gustav Carus, Dresden, Germany.
69 37. Institute of Medical Genetics and Human Genetics, Charite-Universitätsmedizin Berlin, Berlin, Germany.
70 38. Department of Human Genetics, Wellcome Sanger Institute, Wellcome Genome Campus, Hinxton, Cambridge, UK.
71 39. The Department of Clinical Immunology and Allergy, St James's University Hospital, Leeds, UK.
72 40. The NIHR Leeds Biomedical Research Centre and Leeds Institute of Rheumatic and Musculoskeletal Medicine, Leeds, UK.
73 41. These authors led the analysis: James E. D. Thaventhiran, Hana Lango Allen, Oliver S. Burren, William Rae
74 42. These authors contributed equally: Daniel Greene, Emily Staples, Zinan Zhang, J. Henry R. Farmery
75 43. These authors helped supervise this work: Taco W. Kuijpers, Ernest Turro, Willem H. Ouwehand, Adrian J. Thrasher
76

77 **Abstract**

78

79 Primary immunodeficiency (PID) is characterised by recurrent and often life-threatening infections,
80 autoimmunity and cancer, and it presents major diagnostic and therapeutic challenges. Although the
81 most severe forms present in early childhood, the majority of patients present in adulthood, typically
82 with no apparent family history and a variable clinical phenotype of widespread immune dysregulation:
83 about 25% of patients have autoimmune disease, allergy is prevalent, and up to 10% develop lymphoid
84 malignancies¹⁻³. Consequently, in sporadic PID genetic diagnosis is difficult and the role of genetics is not
85 well defined. We addressed these challenges by performing whole genome sequencing (WGS) of a large
86 PID cohort of 1,318 participants. Analysis of coding regions of 886 index cases found disease-causing
87 mutations in known monogenic PID genes in 10.3%, while a Bayesian approach (BeviMed⁴) identified
88 multiple potential new candidate genes, including *IVNS1ABP*. Exploration of the non-coding genome
89 revealed deletions in regulatory regions which contribute to disease causation. Finally, a genome-wide
90 association study (GWAS) identified PID-associated loci and uncovered evidence for co-localisation of,
91 and interplay between, novel high penetrance monogenic variants and common variants (at the *PTPN2*
92 and *SOCS1* loci). This begins to explain the contribution of common variants to variable penetrance and
93 phenotypic complexity in PID. Thus, a cohort-based WGS approach to PID diagnosis can increase
94 diagnostic yield while deepening our understanding of the key pathways influencing human immune
95 responsiveness.

96

97 The phenotypic heterogeneity of PID leads to diagnostic difficulty, and almost certainly to an
98 underestimation of its true incidence. Our cohort reflects this heterogeneity, though it is dominated by
99 adult onset, sporadic antibody deficiency-associated PID (AD-PID: comprising Common Variable
100 Immunodeficiency (CVID), Combined Immunodeficiency (CID) and isolated antibody deficiency).
101 Identifying a specific genetic cause of PID can facilitate definitive treatment including haematopoietic
102 stem cell transplantation, genetic counselling, and the possibility of gene-specific therapy² while
103 contributing to our understanding of the human immune system⁵. Unfortunately, only 29% of patients
104 with PID have a genetic cause of their disease identified⁶, with the lowest rate in patients who present
105 as adults and have no apparent family history. While variants in over 300 genes have been described as
106 monogenic causes of PID³, it is often difficult to match the clinical phenotype to a known genetic cause,
107 because phenotypes are heterogeneous and disease penetrance is often low^{2,7}. Furthermore, a common
108 variant analysis of CVID identified new disease-associated loci, and raised the possibility that common
109 variants may impact upon clinical presentation⁸. We therefore investigated whether applying WGS
110 across a “real world” PID cohort might illuminate the complex genetics of the range of conditions
111 collectively termed PID: the approach is summarised in **Extended Data Fig. 1**.

112

113 **Patient cohort**

114 We sequenced 1,318 individuals recruited as part of the PID domain of the United Kingdom NIHR
115 BioResource - Rare Diseases program (NBR-RD; **Extended Data Fig.2; Supplementary Methods**). The
116 cohort comprised of both sporadic and familial PID patients (N=974) and family members. Of the
117 patients, 886 were index cases who fell into one of the diagnostic categories of the European Society for
118 Immunodeficiencies (ESID) registry diagnostic criteria (**Fig. 1a; Extended Data Table 1**). This cohort
119 represents a third of CVID and half of CID patients registered in the UK⁹. Clinical phenotypes were
120 dominated by adult-onset sporadic AD-PID: all had recurrent infections, 28% had autoimmunity, and 8%
121 had malignancy (**Fig. 1a-b, Extended Data Table 2**), mirroring the UK national PID registry⁶.

122

123 **Identification of Pathogenic Variants in Known Genes**

124 We analysed coding regions of genes with previously reported disease-causing variants in PID¹⁰
125 (**Methods**). Based on filtering criteria for diagnostic reporting according to the American College of
126 Medical Genetics (ACMG) guidelines¹¹ and described in the Methods, we identified and reported to the
127 referring clinicians 104 known or likely pathogenic variants in 91 index cases (10.3%) across 41 genes
128 implicated in monogenic disease (**Fig. 1c; Supplementary Table 1**). 60 patients (6.8%) had a previously
129 reported pathogenic variant in the disease modifier *TNFRSF13B* (*TACI*), increasing the proportion of
130 cases with a reportable variant to 17.0% (151 patients). Interestingly, 5 patients with a monogenic
131 diagnosis (in *BTK*, *LRBA*, *MAGT1*, *RAG2*, *SMARCA1*) also had a pathogenic *TNFRSF13B* variant. Of the
132 103 monogenic variants we report here, 69 (67.0%) had not been previously described (**Supplementary**
133 **Table 1**) and 8 were structural variants, including single exon and non-coding promoter deletions
134 unlikely to have been detected by whole exome sequencing¹².

135 In 22 patients with variants in 14 genes (34% of 41 identified genes) reported as pathogenic, the
136 clinical presentation deviated from the phenotypes typically associated with those genes. One
137 example was chronic mucocutaneous candidiasis (CMC), which is the trigger for clinical genetic testing
138 for *STAT1* GOF variants, as CMC was reported in 98% of such patients^{13,14}. Now this series, along with
139 single case reports^{15,16}, indicate *STAT1* GOF may present with phenotypes as diverse as CVID or
140 primary antibody deficiency. Since many PID-associated genes were initially discovered in a small
141 number of familial cases, it is not surprising that the phenotypes described in the literature do not
142 reflect the true clinical diversity. Thus, a cohort-based WGS approach to PID provides a diagnostic
143 yield even in a predominantly sporadic cohort, allows diagnoses which are not constrained by pre-

144 existing assumptions about genotype-phenotype relationships, and suggests caution in the use of
145 clinical phenotype in targeted gene screening and interpreting PID genetic data.

146

147 **An approach to prioritising candidate PID-associated genes in a WGS cohort**

148 We next determined whether the cohort-based WGS approach could identify new genetic associations
149 with PID. We included all 886 index cases in a single cohort in order to optimise statistical power, and
150 because genotype-phenotype correlation in PID is incompletely understood. We applied a Bayesian
151 inference procedure, named BeviMed⁴, and used it to determine posterior probabilities of association
152 (PPA) between each gene and case/control status of the 886 index cases and 9,283 unrelated controls
153 (**Methods**). We obtained a BeviMed PPA for 31,350 genes in the human genome; the 25 highest ranked
154 genes are shown in **Fig. 2a** (see also **Supplementary Table 2** and **Supplementary Note 2**). Overall, genes
155 with BeviMed PPA>0.1 were strongly enriched for known PID genes (odds ratio = 15.1, $P = 3.1 \times 10^{-8}$
156 Fisher's Exact test), demonstrating that a statistical genetic association approach can identify genes
157 causal for PID.

158 This method produces a *posterior probability* of association, therefore it is inevitable that, where this is
159 <1, some genes identified will not end up being found to be causal. Such false positives are an integral
160 feature of a method which does not provide statistical proof of causality, but rather ranks/prioritises
161 genes for subsequent functional assessment. They can be minimised by ensuring reasonable
162 assumptions in the Bayesian algorithm⁴, and by taking care to detect and minimise relatedness and
163 population stratification (detailed in **Methods, Supplementary Note 2** and **Supplementary Table 2**).

164 *NFKB1* and *ARPC1B* were first associated with PID in the literature as a result of familial co-segregation
165 studies^{17,18}, and were highly ranked in the BeviMed analysis, validating it as a gene-discovery tool in PID.
166 *NFKB1* had the strongest probability of association ($PPA=1-(1.25 \times 10^{-8})$), driven by truncating
167 heterozygous variants in 13 patients – leading to our report of *NFKB1* haploinsufficiency as the
168 commonest monogenic cause of CVID¹⁹. Association of *ARPC1B* with PID ($PPA=0.18$) was identified by
169 BeviMed based on two recessive cases; one the first reported to link this gene to PID¹⁸ and the other
170 described below.

171 To further demonstrate the effectiveness of BeviMed at prioritizing PID-related genetic variants in the
172 cohort, we selected *IVNS1ABP* for validation. BeviMed enrichment ($PPA=0.33$) of *IVNS1ABP* was driven
173 by three independent heterozygous protein-truncating variants, suggesting haploinsufficiency, while no
174 such variants were observed in controls (**Fig. 2b**). A pathogenic role for *IVNS1ABP* was supported by its
175 intolerance to loss-of-function ($pLI=0.994$) and a distinctive clinical similarity between the patients – all
176 had severe warts (**Supplementary Note 1**). *IVNS1ABP* protein expression was around 50% of control,
177 consistent with haploinsufficiency (**Fig. 2c**). The patients also shared a previously undescribed peripheral
178 leukocyte phenotype – with low/normal CD4+ T cells and B cells and aberrant increased expression of
179 CD127 and PD-1 on naive T cells (**Fig. 2d,e**). Taken together, these data implicate *IVNS1ABP*
180 haploinsufficiency as a novel monogenic cause of PID (**Supplementary Note 1**).

181 The identification of both known and new PID genes using BeviMed underlines its effectiveness in
182 cohorts of unrelated patients with sporadic disease. As the PID cohort grows, even very rare causes of
183 PID should be detectable with a high positive predictive value (**Extended Data Fig. 3**).

184

185 **Identification of regulatory elements contributing to PID**

186 Sequence variation within non-coding regions of the genome can have profound effects on gene
187 expression and would be expected to contribute to susceptibility to PID. We combined rare variant and
188 large deletion (>50bp) events with a tissue-specific catalogue of cis-regulatory elements (CREs)²⁰,

189 generated using promoter capture Hi-C (pcHi-C)²¹, to prioritise putative causal PID genes (**Methods**). We
190 limited our initial analysis to rare large deletions overlapping exon, promoter or ‘super-enhancer’ CREs
191 of known PID genes. No homozygous deletions affecting CREs were identified, so we sought individuals
192 with two or more heterozygous variants comprising a CRE deletion with either a rare coding variant or
193 another large deletion in a pcHi-C linked gene. Such candidate compound heterozygote (cHET) variants
194 had the potential to cause recessive disease. Out of 22,296 candidate cHET deletion events, after
195 filtering by MAF, functional score and known PID gene status, we obtained 10 events (**Supplementary**
196 **Table 3, Extended Data Fig. 4**); the confirmation of three is described.

197 The *LRBA* and *DOCK8* cHET variants were functionally validated (**Extended Data Figs. 4 and 5**). In these
198 two cases SV deletions encompassed both non-coding CREs and coding exons, but the use of WGS PID
199 cohorts to detect a contribution of CREs confined to the non-coding genome would represent a major
200 advance in PID pathogenesis and diagnosis. *ARPC1B* fulfilled this criterion, with its BeviMed association
201 partially driven by a patient cHET for a novel p.Leu247Glyfs*25 variant resulting in a premature stop,
202 and a 9Kb deletion spanning the promoter region including an untranslated first exon (**Fig. 3a**) that has
203 no coverage in the ExAC database (<http://exac.broadinstitute.org>). Two unaffected first-degree relatives
204 were heterozygous for the frameshift variant, and two for the promoter deletion (**Fig. 3b**), confirming
205 compound heterozygosity in the patient. Western blotting demonstrated complete absence of ARPC1B
206 and raised ARPC1A in platelets²²(**Fig. 3c**). *ARPC1B* mRNA was almost absent from mononuclear cells in
207 the patient and was reduced in a clinically unaffected sister carrying the frameshift mutation
208 (**Supplementary Note 1**). An allele specific expression assay demonstrated that the promoter deletion
209 essentially abolished mRNA expression (**Supplementary Note 1**). ARPC1B is part of the Arp2/3 complex
210 necessary for normal actin assembly in immune cells²³, and monocyte-derived macrophages from the
211 patient had an absence of podosomes, phenocopying deficiency of the Arp2/3 regulator WASp (**Fig. 3d**).

212 While examples of bi-allelic coding variants have been described as causing PID (e.g.^{24,25}), here we
213 demonstrate the utility of WGS for detecting compound heterozygosity for a coding variant and a non-
214 coding CRE deletion - a further advantage of a WGS approach to PID diagnosis. Improvements in analysis
215 methodology, cohort size and better annotation of regulatory regions will be required to explore the
216 non-coding genome more fully and discover further disease-causing genetic variants.

217

218 **GWAS of the WGS cohort reveals PID-associated loci**

219 The diverse clinical phenotype and variable within-family disease penetrance of PID may be in part due
220 to stochastic events (e.g. unpredictable pathogen transmission) but may also have a genetic basis. We
221 therefore performed a GWAS of common SNPs (minor allele frequency (MAF)>0.05), restricted to 733
222 AD-PID cases (**Fig. 1a**) to reduce phenotypic heterogeneity (see **Methods**), and 9,225 unrelated NBR-RD
223 controls, and performed a fixed effect meta-analysis of this AD-PID GWAS with a previous CVID study
224 ImmunoChip study (778 cases, 10,999 controls)⁸. This strengthened known MHC and 16p13.13
225 associations⁸, and found suggestive associations including at 3p24.1 within the promoter region of
226 *EOMES* and at 18p11.21 proximal to *PTPN2*. We also examined SNPs of intermediate frequency
227 (0.005<MAF<0.05) in AD-PID, identifying *TNFRSF13B* p.Cys104Arg variant²⁶ (OR=4.04, P = 1.37x10⁻¹²)
228 (**Fig. 4a, Extended Data Table 3, Extended Data Fig. 6, Supplementary Note 3**). Conditional analysis of
229 the MHC locus revealed independent signals at the Class I and Class II regions, driven by amino-acid
230 changes in the *HLA-B* and *HLA-DRB1* genes known to impact upon peptide binding (**Extended Data Fig.**
231 **7**). We next examined the enrichment of non-MHC AD-PID associations in 9 other diseases, finding
232 enrichment for allergic and immune-mediated diseases (IMD), suggesting that dysregulation of common
233 pathways contributes to susceptibility to both (**Supplementary Note 4**).

234

235 **GWAS data allows identification of candidate monogenic PID genes and disease-modifying variants**

236 To investigate whether loci identified by GWAS of AD-PID and other IMD might be used to prioritize
237 novel candidate monogenic PID genes, we used the data-driven pHiC omnibus gene score (COGS)
238 approach²¹ (**Methods, Supplementary Table 4**). We selected six protein-coding genes with above
239 average prioritisation scores in one or more diseases (**Fig. 4b**), and identified a single protein truncating
240 variant in each of *ETS1*, *SOCS1* and *PTPN2* genes, all occurring exclusively in PID patients. *SOCS1* and
241 *PTPN2* variants were analysed further.

242
243 *SOCS1* limits phosphorylation of targets including STAT1, and is a key regulator of IFN- γ signalling²⁷. The
244 patient with a heterozygous *de-novo* protein-truncating *SOCS1* variant (p.Met161Alafs*46) presented
245 with CVID complicated by lung and liver inflammation. GeneMatcher²⁸ identified an independent
246 pedigree with a protein truncating variant p.Tyr64* in *SOCS1*. All patients showed low/normal numbers
247 of B cells, a Th1-skewed memory CD4+ population and reduced T regulatory (Treg) cells (**Supplementary**
248 **Note 1**). *Socs1* haploinsufficient mice also demonstrate B lymphopenia^{27,29}, a Th1 skew, decreased
249 Tregs³⁰ and immune-mediated liver inflammation³¹. In patients' T cell blasts, *SOCS1* was reduced and
250 IFN- γ induced STAT1 phosphorylation was increased (**Fig. 4c**). Taken together this is consistent with
251 *SOCS1* haploinsufficiency causing PID. The initial patient also carried the *SOCS1* pHiC-linked 16p13.13
252 risk-allele identified in the AD-PID GWAS (**Supplementary Note 3**) in *trans* with the novel *SOCS1*-
253 truncating variant (**Supplementary Note 1**); such compound heterozygosity suggests common and rare
254 variants might combine to impact upon disease phenotype, a possibility explored further below.

255 A more detailed example of an interplay between rare and common variants is provided by a family
256 containing *PTPN2* variants (**Fig. 4d**). *PTPN2* encodes the non-receptor T-cell protein tyrosine
257 phosphatase (TC-PTP) that negatively regulates immune responses by dephosphorylation of proteins
258 mediating cytokine signalling. *PTPN2* deficient mice are B cell lymphopenic^{32,33} and haematopoietic
259 deletion leads to B and T cell proliferation and autoimmunity³⁴. A novel premature stop-gain at p.Glu291
260 was identified in a "sporadic" case presenting with CVID at age 20; he had B lymphopenia, low IgG,
261 rheumatoid-like polyarthropathy, severe recurrent bacterial infections, splenomegaly and inflammatory
262 lung disease. His mother, also heterozygous for the *PTPN2* truncating variant, had systemic lupus
263 erythematosus (SLE), insulin-dependent diabetes mellitus, hypothyroidism and autoimmune
264 neutropenia (**Supplementary Note 1**). Gain-of-function variants in *STAT1* can present as CVID
265 (**Supplementary Table 1**) and TC-PTP, like *SOCS1*, reduces phosphorylated *STAT1* (**Fig. 4e**). Both mother
266 and son demonstrated reduced T cell TC-PTP expression and *STAT1* hyperphosphorylation, more
267 pronounced in the index case and similar to both *SOCS1* haploinsufficient and *STAT1* GOF patients (**Fig.**
268 **4f**). Thus *PTPN2* haploinsufficiency represents a new cause of PID that acts, at least in part, through
269 increased phosphorylation of *STAT1*. Reports that use of the Janus Kinase 1 and 2 inhibitor ruxolitinib
270 is effective in controlling autoimmunity in *STAT1*-GOF patients³⁵, suggests it might be effective in *SOCS1*
271 and *PTPN2* deficiency.

272 The index case, but not his mother, carried the G allele of variant rs2847297 at the *PTPN2* locus, an
273 expression quantitative trait locus (eQTL)³⁶ previously associated with rheumatoid arthritis³⁷. His
274 brother, healthy apart from severe allergic nasal polyposis, was heterozygous at rs2847297 and did not
275 inherit the rare variant (**Fig. 4d**). Allele-specific expression analysis demonstrated reduced *PTPN2*
276 transcription from the rs2847297-G allele, explaining the lower expression of TC-PTP and greater
277 persistence of pSTAT1 in the index case compared to his mother (**Fig. 4g**). This could explain the
278 variable disease penetrance in this family, with *PTPN2* haploinsufficiency alone driving autoimmunity in
279 the mother, but the additional impact of the common variant on the index case causing
280 immunodeficiency. The family illustrates the strength of cohort-wide WGS approach to PID diagnosis, by

281 revealing both a new monogenic cause of disease, and how the interplay between common and rare
282 genetic variants may contribute to the variable clinical phenotypes of PID.

283 In summary, we show that cohort-based WGS in PID is a powerful approach to provide diagnosis of
284 known genetic defects, and discover new coding and non-coding variants associated with disease
285 (comparison of WGS with other methodologies; **Supplementary Note 5**). Improved analysis
286 methodology and better integration of parallel datasets, such as GWAS and cell surface or metabolic
287 immunophenotyping, will allow further exploration of the non-coding space, enhancing diagnostic yield.
288 Such an approach promises to transform our understanding of genotype-phenotype relationships in PID
289 and related immune-mediated conditions, and could redefine the clinical boundaries of
290 immunodeficiency, add to our understanding of human immunology, and ultimately improve patient
291 outcomes.

292

293 **References**

294

- 295 1. Gathmann, B. *et al.* Clinical picture and treatment of 2212 patients with common variable
296 immunodeficiency. *J. Allergy Clin. Immunol.* **134**, 116-126.e11 (2014).
- 297 2. Lenardo, M., Lo, B. & Lucas, C. L. Genomics of Immune Diseases and New Therapies. *Annu. Rev.*
298 *Immunol.* **34**, 121–149 (2016).
- 299 3. Bousfiha, A. *et al.* The 2017 IUIS Phenotypic Classification for Primary Immunodeficiencies. *J. Clin.*
300 *Immunol.* **38**, 129–143 (2018).
- 301 4. Greene, D., Richardson, S. & Turro, E. A Fast Association Test for Identifying Pathogenic Variants
302 Involved in Rare Diseases. *Am. J. Hum. Genet.* **101**, 104–114 (2017).
- 303 5. Casanova, J.-L. Human genetic basis of interindividual variability in the course of infection. *Proc.*
304 *Natl. Acad. Sci. U. S. A.* **112**, E7118-27 (2015).
- 305 6. Edgar, J. D. M. *et al.* The United Kingdom Primary Immune Deficiency (UKPID) Registry: report of
306 the first 4 years' activity 2008-2012. *Clin. Exp. Immunol.* **175**, 68–78 (2014).
- 307 7. Pan-Hammarström, Q. *et al.* Reexamining the role of TACI coding variants in common variable
308 immunodeficiency and selective IgA deficiency. *Nat. Genet.* **39**, 429–430 (2007).
- 309 8. Li, J. *et al.* Association of CLEC16A with human common variable immunodeficiency disorder and
310 role in murine B cells. *Nat. Commun.* **6**, 6804 (2015).
- 311 9. Shillitoe, B. *et al.* The United Kingdom Primary Immune Deficiency (UKPID) registry 2012 to 2017.
312 *Clin. Exp. Immunol.* **192**, 284–291 (2018).
- 313 10. Bousfiha, A. *et al.* The 2015 IUIS Phenotypic Classification for Primary Immunodeficiencies. *J. Clin.*
314 *Immunol.* **35**, 727–38 (2015).
- 315 11. Richards, S. *et al.* Standards and guidelines for the interpretation of sequence variants: a joint
316 consensus recommendation of the American College of Medical Genetics and Genomics and the
317 Association for Molecular Pathology. *Genet. Med.* **17**, 405–423 (2015).
- 318 12. Fromer, M. *et al.* Discovery and statistical genotyping of copy-number variation from whole-
319 exome sequencing depth. *Am. J. Hum. Genet.* **91**, 597–607 (2012).
- 320 13. van de Veerdonk, F. L. *et al.* STAT1 Mutations in Autosomal Dominant Chronic Mucocutaneous
321 Candidiasis. *N. Engl. J. Med.* **365**, 54–61 (2011).
- 322 14. Liu, L. *et al.* Gain-of-function human STAT1 mutations impair IL-17 immunity and underlie chronic
323 mucocutaneous candidiasis. *J. Exp. Med.* **208**, 1635–48 (2011).
- 324 15. Breuer, O. *et al.* Autosomal dominant gain of function STAT1 mutation and severe bronchiectasis.
325 *Respir. Med.* **126**, 39–45 (2017).
- 326 16. Toubiana, J. *et al.* Heterozygous STAT1 gain-of-function mutations underlie an unexpectedly
327 broad clinical phenotype. *Blood* **127**, 3154 (2016).
- 328 17. Fliegau, M. *et al.* Haploinsufficiency of the NF- κ B1 Subunit p50 in Common Variable
329 Immunodeficiency. *Am. J. Hum. Genet.* **97**, 389–403 (2015).
- 330 18. Kuijpers, T. W. *et al.* Combined immunodeficiency with severe inflammation and allergy caused

- 331 by ARPC1B deficiency. *J. Allergy Clin. Immunol.* **140**, 273-277.e10 (2017).
- 332 19. Tuijnenburg, P. *et al.* Loss-of-function nuclear factor κ B subunit 1 (NFKB1) variants are the most
333 common monogenic cause of common variable immunodeficiency in Europeans. *J. Allergy Clin.*
334 *Immunol.* **142**, 1285–1296 (2018).
- 335 20. Hnisz, D. *et al.* Super-Enhancers in the Control of Cell Identity and Disease. *Cell* **155**, 934–947
336 (2013).
- 337 21. Javierre, B. M. *et al.* Lineage-Specific Genome Architecture Links Enhancers and Non-coding
338 Disease Variants to Target Gene Promoters. *Cell* **167**, 1369-1384.e19 (2016).
- 339 22. Kahr, W. H. A. *et al.* Loss of the Arp2/3 complex component ARPC1B causes platelet
340 abnormalities and predisposes to inflammatory disease. *Nat. Commun.* **8**, 14816 (2017).
- 341 23. Burns, S., Cory, G. O., Vainchenker, W. & Thrasher, A. J. Mechanisms of WASp-mediated
342 hematologic and immunologic disease. *Blood* **104**, 3454 LP – 3462 (2004).
- 343 24. Engelhardt, K. R. *et al.* Identification of Heterozygous Single- and Multi-exon Deletions in IL7R by
344 Whole Exome Sequencing. *J. Clin. Immunol.* **37**, 42–50 (2017).
- 345 25. Schepp, J. *et al.* Deficiency of Adenosine Deaminase 2 Causes Antibody Deficiency. *J. Clin.*
346 *Immunol.* **36**, 179–186 (2016).
- 347 26. Salzer, U. *et al.* Mutations in TNFRSF13B encoding TACI are associated with common variable
348 immunodeficiency in humans. *Nat. Genet.* **37**, 820–828 (2005).
- 349 27. Alexander, W. S. *et al.* SOCS1 is a critical inhibitor of interferon gamma signaling and prevents the
350 potentially fatal neonatal actions of this cytokine. *Cell* **98**, 597–608 (1999).
- 351 28. Sobreira, N., Schiettecatte, F., Valle, D. & Hamosh, A. GeneMatcher: A Matching Tool for
352 Connecting Investigators with an Interest in the Same Gene. *Hum. Mutat.* **36**, 928–930 (2015).
- 353 29. Starr, R. *et al.* Liver degeneration and lymphoid deficiencies in mice lacking suppressor of
354 cytokine signaling-1. *Proc. Natl. Acad. Sci. U. S. A.* **95**, 14395–9 (1998).
- 355 30. Horino, J. *et al.* Suppressor of cytokine signaling-1 ameliorates dextran sulfate sodium-induced
356 colitis in mice. *Int. Immunol.* **20**, 753–62 (2008).
- 357 31. Yoshida, T. *et al.* SOCS1 is a suppressor of liver fibrosis and hepatitis-induced carcinogenesis. *J.*
358 *Exp. Med.* **199**, 1701–7 (2004).
- 359 32. Bourdeau, A. *et al.* TC-PTP-deficient bone marrow stromal cells fail to support normal B
360 lymphopoiesis due to abnormal secretion of interferon- γ . *Blood* **109**, 4220–8 (2007).
- 361 33. You-Ten, K. E. *et al.* Impaired bone marrow microenvironment and immune function in T cell
362 protein tyrosine phosphatase-deficient mice. *J. Exp. Med.* **186**, 683–93 (1997).
- 363 34. Wiede, F., Sacirbegovic, F., Leong, Y. A., Yu, D. & Tiganis, T. PTPN2-deficiency exacerbates T
364 follicular helper cell and B cell responses and promotes the development of autoimmunity. *J.*
365 *Autoimmun.* **76**, 85–100 (2017).
- 366 35. Forbes, L. R. *et al.* Jakinibs for the treatment of immune dysregulation in patients with gain-of-
367 function signal transducer and activator of transcription 1 (STAT1) or STAT3 mutations. *J. Allergy*
368 *Clin. Immunol.* **142**, 1665–1669 (2018).
- 369 36. Kilpinen, H. *et al.* Common genetic variation drives molecular heterogeneity in human iPSCs.
370 *Nature* **546**, 370–375 (2017).
- 371 37. Okada, Y. *et al.* Meta-analysis identifies nine new loci associated with rheumatoid arthritis in the
372 Japanese population. *Nat. Genet.* **44**, 511–6 (2012).
- 373

374 **Figure Legends**

375

376 **Figure 1. Description of the immunodeficiency cohort and disease associations in coding regions. (a)**

377 Number of index cases recruited under different phenotypic categories (red – adult cases, blue –
378 paediatric cases, lighter shade – sporadic (no family history of PID), darker shade - family history of PID).
379 CVID – Common variable immunodeficiency, CID – combined immunodeficiency, and SCID – severe
380 combined immunodeficiency. **(b)** Number of index cases with malignancy, autoimmunity and CD4+
381 lymphopenia. (black bar – total number of cases, blue bar - number of cases with AD-PID phenotype). **(c)**
382 Number of patients with reported genetic findings subdivided by gene. Previously reported variants are
383 those identified as immune disease-causing in the HGMD-Pro database.

384 **Figure 2. Discovery of novel PID genes in a large cohort WGS analysis. (a)** BeviMed assessment of
385 enrichment for candidate disease-causing variants in individual genes, in the PID cohort relative to the
386 rest of the NBR-RD cohort (cases n=886, controls n= 9,284). The top 25 candidate genes are shown.
387 Genes highlighted in yellow are those flagged as potentially confounded by population stratification (see
388 **Supplementary Note 2**). Prioritized genes known to cause PID according to the International Union of
389 Immunological Societies (IUIS) in 2015 (blue)¹⁰ and 2017 (red)³. **(b)** Pedigrees of 3 unrelated kindreds
390 with damaging *IVNS1ABP* variants and linear protein position of variants. **(c)** Western blot of *IVNS1ABP*
391 and *GAPDH* in whole cell lysates of PBMCs. (Top) Representative blot from A.II.1 (P) and Control (C). For
392 gel source data, see Supplementary Figure 1. (Bottom) Graph of relative *IVNS1ABP* normalized to
393 *GAPDH*. (representative of 4 independent experiments). **(d)** Immunophenotyping of CD3+ T cells, CD4+,
394 CD8+ T cells, and CD19+ B cells in C = healthy controls (n=20) and P = *IVNS1ABP* patients (n=4).
395 **(e)** Assessment of CD127 and PD-1 expression in naïve T cells. (Left) Representative gating of naïve
396 (CD45RA+ CD62L+) CD4+ T cells in a control and B.II.1. (Middle) FACS histograms of PD-1 and CD127 from
397 controls and *IVNS1ABP* patients (B.II.1 and A.II.1). (Right) PD-1 and CD127 mean fluorescence intensity
398 (MFI) values from controls (C, n=20) and patients (P, n=4). All tests two-sided Mann Whitney U. Lines
399 present means, bars = S.E.M.

400 **Figure 3. Assessment of WGS data for regulatory region deletions that impact upon PID. (a)** Genomic
401 configuration of the *ARPC1B* gene locus highlighting the compound heterozygous gene variants. ExAC
402 shows that the non-coding deletion is outside of the exome-targeted regions. **(b)** Pedigree of patient in
403 (a) and co-segregation of *ARPC1B* genotype (wt – wild-type, del – deletion, fs – frameshift). **(c)** Western
404 blot of *ARPC1A* and *ARPC1B* in neutrophil and platelet lysates from the patient (P) and control (C, n=1).
405 For gel source data, see Supplementary Figure 1. **(d)** Podosomes were identified by staining adherent,
406 fixed monocyte-derived macrophages for vinculin, phalloidin and the nuclear stain DAPI. Quantification
407 was performed by counting podosomes on at least 100 cells per sample from 10 fields of view at 60x
408 magnification.

409 **Figure 4. Antibody deficiency (AD-PID) GWAS identifies common variants that mediate disease risk**
410 **and suggests novel monogenic candidate genes. (a)** A composite Manhattan plot for the AD-PID GWAS.
411 Blue – common variants (MAF>0.05) analysed in this study (NBR-RD) only (cases n=773, controls
412 n=9,225), red – variants from fixed effects meta-analysis with data from Li *et al.* (cases n=1,511, controls
413 n=20,224); and purple – genome-wide significant low frequency (0.005<MAF<0.05) variants in
414 *TNFRSF13B* locus. Loci of interest are labelled with putative causal protein coding gene names. **(b)** COGS
415 prioritisation scores of candidate monogenic causes of PID using previous autoimmune targeted
416 genotyping studies (**Supplementary Table 4**) across suggestive AD-PID loci (n=4). For clarity, only
417 diseases prioritising one or more genes are shown. CEL – coeliac disease, CRO- Crohn’s disease, UC –
418 ulcerative colitis, MS – multiple sclerosis, PBC – primary biliary cirrhosis and T1D – type 1 diabetes **(c)**
419 Graph of relative pSTAT1 and SOCS1 in lysates made from 2 hour IFN-γ treated T cell blasts from SOCS1

420 mutation patients and controls. (Lines present mean, error bars=S.E.M.) **(d)** The pedigree of the *PTPN2*
421 mutation patient. Carriers of the rs2847297-G risk allele are indicated. **(e)** Simplified model of how
422 SOCS1 and TC-PTP limit the phosphorylated-STAT1 triggered by interferon signalling. **(f)** Graph of
423 relative PTPN2 and pSTAT1 from the indicated patients and controls, in lysates made from T cell blasts
424 incubated \pm IFN- γ for 2 hours. (PTPN2 normalized to tubulin level, pSTAT1 normalised to STAT1 levels,
425 representative of 2 independent experiments)

426

427 **Methods**

428 PID cohort

429 The PID patients and their family members were recruited by specialists in clinical immunology across 26
430 hospitals in the UK, and one each from the Netherlands, France and Germany. The recruitment criteria
431 were intentionally broad, and included the following: clinical diagnosis of common variable
432 immunodeficiency disorder (CVID) according to internationally established criteria (**Extended Data Table**
433 **1**); extreme autoimmunity; or recurrent and/or unusual severe infections suggestive of defective innate
434 or cell-mediated immunity. Patients with known secondary immunodeficiencies caused by cancer or HIV
435 infection were excluded. Although screening for more common and obvious genetic causes of PID prior
436 to enrolment into this WGS study was encouraged, it was not a requirement. Consequently, a minority
437 of patients (16%) had some prior genetic testing, from single gene Sanger sequencing or MLPA to a gene
438 panel screen. Paediatric and familial cases were less frequent in our cohort, in part reflecting that
439 genetic testing is more frequently performed in more severe cases: 31% of paediatric onset cases had
440 prior genetic testing compared to 10% of adult index cases (**Extended Data Fig. 2**).

441 To expedite recruitment a minimal clinical dataset was required for enrolment, though more detail was
442 often provided. There was a large variety in patients' phenotypes, from simple "chest infections" to
443 complex syndromic features, and the collected phenotypic data of the sequenced individuals ranged
444 from assigned disease category only to detailed clinical synopsis and immunophenotyping data. The
445 clinical subsets used to subdivide PID patients were based on ESID definitions, as shown in **Extended**
446 **Data Table 1**. The final PID cohort that we sequenced comprised of 886 index cases, 88 affected
447 relatives, and 344 family members unaffected at the time of recruitment.

448 To facilitate GWAS analysis by grouping patients with a degree of phenotypic coherence while excluding
449 some distinct and very rare clinical subtypes of PID that may have different aetiologies, a group of
450 patients was determined to have antibody deficiency-associated PID (AD-PID). This group comprised 733
451 of the 886 unrelated index cases, and included all patients with CID, CVID or Antibody Defect ticked on
452 the recruitment form, together with patients requiring IgG replacement therapy and those with
453 specified low levels of IgG/A/M. SCID patients satisfying these AD criteria were not assigned to the AD-
454 PID cohort.

455 WGS data processing

456 Details of DNA sample processing, whole genome sequencing, data processing pipeline, quality checks,
457 alignment and variant calling, ancestry and relatedness estimation, variant normalisation and
458 annotation, large deletion calling and filtering, and allele frequency calculations, are described in³⁸.
459 Briefly, DNA or whole blood EDTA samples were processed and quality checked according to standard
460 laboratory practices and shipped on dry ice to the sequencing provider (Illumina Inc, Great Chesterford,
461 UK). Illumina Inc performed further QC array genotyping, before fragmenting the samples to 450bp
462 fragments and processing with the Illumina TruSeq DNA PCR-Free Sample Preparation kit (Illumina Inc.,
463 San Diego, CA, USA). Over the three-year duration of the sequencing phase of the project, different
464 instruments and read lengths were used: for each sample, either 100bp reads on three HiSeq2500 lanes;
465 or 125bp reads on two HiSeq2500 lanes; or 150bp reads on a single HiSeq X lane. Each delivered
466 genome had a minimum 15X coverage over at least 95% of the reference autosomes. Illumina
467 performed the alignment to GRCh37 genome build and SNV/InDel calling using their Isaac software,
468 while large deletions were called with their Manta and Canvas algorithms. The WGS data files were
469 received at the University of Cambridge High Performance Computing Service (HPC) for further QC and
470 processing by our Pipeline team.

471 For each sample, we estimated the sex karyotype and computed pair-wise kinship coefficients (full
472 methods described in⁴⁷), which allowed us to identify sample swaps and unintended duplicates, assign
473 ethnicities, generate networks of closely related individuals (sometimes undeclared relatives from
474 across different disease domains) and a maximal unrelated sample set (for the purposes of allele
475 frequency estimation and control dataset in case-control analyses). Variants in the gVCF files were

476 normalised and loaded into an HBase database, where Overall Pass Rate (OPR) was computed within
477 each of the three read length batches, and the lowest of these OPR values (minOPR) assigned to each
478 variant. The rare variant analyses presented here are based on SNVs/InDels with minOPR>0.98. Variants
479 were annotated with Sequence Ontology terms according to their predicted consequences, their
480 frequencies in other genomic databases (gnomAD, UK10K, 1000 Genomes), if they have been associated
481 with a disease according to the HGMD Pro database, and internal metrics (AN, AC, AF, OPR).

482 Large deletions (those >50bp in length, defined by Illumina) were merged and analysed collectively, as
483 described in³⁸. Briefly, sample-level calls by the two algorithms, Manta (which uses read and mate-pair
484 alignment information) and Canvas (which relies on read depth and is optimised for calls >1kb in length),
485 were combined according to a set of rules³⁸ to generate a high quality set for each sample (and a large
486 number across the project was visually inspected to ensure reasonably high specificity). To exclude
487 common deletions from further rare variant analyses, we included only those that were observed in
488 fewer than 3% of the samples, as described previously³⁹.

489 Diagnostic reporting

490 We screened all genes in the International Union of Immunological Societies (IUIS) 2015 classification for
491 previously reported or likely pathogenic variants. SNVs and small InDels were filtered based on the
492 following criteria: OPR>0.95; having a protein-truncating consequence, gnomAD AF<0.001 and internal
493 AF<0.01; or present in the HGMD Pro database as DM variant. Large deletions called by both Canvas and
494 Manta algorithms, passing standard Illumina quality filters, overlapping at least one exon, and classified
495 as rare by the SVH method were included in the analysis. In order to aid variant interpretation and
496 consistency in reporting, phenotypes were translated into Human Phenotype Ontology (HPO) terms as
497 much as possible. Multi-Disciplinary Team (MDT) then reviewed each variant for evidence of
498 pathogenicity and contribution to the phenotype, and classified them according to the American College
499 of Medical Genetics (ACMG) guidelines¹¹. Only variants classified as Pathogenic or Likely Pathogenic
500 were systematically reported, but individual rare (gnomAD AF<0.001) or novel missense variants that
501 BeviMed analysis (see below) highlighted as having a posterior probability of pathogenicity >0.2 were
502 additionally considered as Variants of Unknown Significance (VUS). If the MDT decided that they were
503 likely to be pathogenic and contribute to the phenotype, they were also reported (**Supplementary Table**
504 **2**). All variants and breakpoints of large deletions reported in this study were confirmed by Sanger
505 sequencing using standard protocols.

506 BeviMed

507 We used BeviMed⁴ to evaluate the evidence for association, in genetically unrelated individuals,
508 between case/control status and rare genetic variants in a locus. For each gene, we inferred a posterior
509 probability of association (PPA) under Mendelian inheritance models (dominant and recessive), and
510 different variant selection criteria ("moderate" and "high" impact variants based on functional
511 consequences predicted by the Variant Effect Predictor⁴⁰). We inferred a PPA across all association
512 models and the mode of inheritance corresponding to the association model with the greatest posterior
513 probability. We used MAF<0.001 and CADD>=10 as these were selection criteria for rare, likely
514 pathogenic variants used in diagnostic reporting. Approximately 1% of all genes (276/31,350¹⁰) have
515 previously been implicated as monogenic causes of PID, and we therefore assumed that a few hundred
516 genes are causal of PID overall. We encoded this assumption conservatively, by assigning a prior
517 probability of 0.01 to the association model for each gene. In addition, we used the default prior
518 (mean=0.85) on the "penetrance" parameter, which represents disease risk for individuals carrying
519 pathogenic configuration of alleles at a gene locus (see ⁴ for a detailed description of all parameters and
520 their default values). We then gave all four combinations of inheritance model and variant selection
521 criteria equal prior probability of association of 0.0025 (1/4 of 0.01). We used uniform priors to ensure
522 that our results did not depend on any knowledge of previous gene or variant associations with disease.
523 We obtained a BeviMed PPA for 31,350 genes in the human genome; the highest ranked genes are
524 shown in **Fig. 2a, Supplementary Note 2** and **Supplementary Table 2**. Overall, genes with BeviMed

525 PPA>0.1 were strongly enriched for known PID genes (odds ratio = 15.1, P = 3.1x10⁻⁸ Fisher's Exact test),
526 demonstrating that a statistical genetic association approach can identify genes causal for PID.

527 Conditional on the association model with the highest posterior probability, the posterior probability
528 that each rare variant is pathogenic was also computed. We used a variant-level posterior probability of
529 pathogenicity >0.2 to select potentially pathogenic missense variants in known PID genes to report back.
530 As detailed in Greene *et al.* (Figure 1 in ⁴) the method was calibrated as part of a simulation study
531 estimating positive predictive value (1-FDR) given a fixed level of power. We then examined the
532 relationship between BeviMed rank and 'known' gene status in the top fifty genes reported; genes with
533 the highest PPA were significantly enriched for known genes (P<0.008 one-sided Wilcoxon rank-sum
534 test). BeviMed's sensitivity in prioritizing genes as causal, even if variants exist in only a few cases, is
535 demonstrated by the observation that of the 8 IUIS-defined causal PID genes in the top 50 (all with a
536 BeviMed PPA>0.2), 3 are driven by 2 or 3 cases, while 5 have between 4 and 16.

537 As allele frequency datasets for non-Europeans are much smaller than for Europeans, potential false
538 positives may be induced by the unintentional inclusion of rare variants observed only in non-European
539 populations⁴¹. Furthermore, whilst the BeviMed analysis was restricted to the set of cases and controls
540 carefully filtered to minimise relatedness, it remains possible that some associations could be false
541 positives due to residual population stratification. We addressed this by flagging variants whose
542 prioritisation was dependent upon cases with non-European ancestry. In addition, where identical ultra-
543 rare variants were shared between cases, we examined the possibility of cryptic relatedness by seeking
544 direct evidence of shared genetic background (**Supplementary Note 2**). These procedures found that
545 population stratification might contribute to the prioritization of 9 candidate genes among the top 25,
546 as highlighted in **Fig. 2a** and **Supplementary Table 2**. Six of these were novel candidates, but that 3 were
547 known causes of PID indicated that population stratification does not always generate false positives –
548 and implicated genes should therefore be flagged rather than excluded from the list. This potential
549 impact of population stratification underlines the importance of subsequent validation of prioritized
550 genes in order to demonstrate causality.

551 The BeviMed probabilistic model, based on dominant and recessive inheritance involving a mixture of
552 pathogenic and benign variants, differs from other popular frequentist methods such as SKAT, and is
553 well-suited to the rare disease scenario. When trained on our dataset, SKAT and BeviMed both
554 identified *NKFB1* as the gene with the strongest association signal, but BeviMed placed 8 IUIS 2017 PID
555 genes in the top 50 results whilst SKAT placed 5, and *ARPC1B* was ranked 38th by BeviMed and 289th by
556 SKAT (out of a total of 31,350 tested genes), consistent with the superiority of BeviMed over SKAT and
557 related methods demonstrated in Greene *et al.*¹.

558 Immunohistochemistry: podosome analysis

559 Frozen peripheral blood mononuclear cells (PBMCs) from healthy donors and patients were thawed and
560 CD14⁺ cells selected using magnetic beads (Miltenyi). 2 x 10⁵ cells/ well in a 24 well plate were seeded
561 on 10ug/ml fibronectin-coated cover slips (R&D systems) in 500ul 20ng/ml macrophage colony
562 stimulating factor (MCSF, Gibco) for 6 days to obtain monocyte-derived macrophages (MDMs). Cells
563 were fixed with paraformaldehyde 4% (Thermo Fisher Scientific) for 10 minutes on ice followed by 8%
564 for 20 minutes at room temperature, permeabilised with 0.1% triton (Sigma) for 5 minutes at room
565 temperature and non-specific binding reduced by blocking with 5% BSA/PBS for 1 hour at room
566 temperature. Cells were incubated with primary anti-vinculin antibody (Sigma 1:200) for 1 hour at room
567 temperature, washed twice with PBS and incubated with secondary antibody conjugated to Alexa Fluor
568 488 (1:500 Life Technologies) and phalloidin-conjugated to Alexa Fluor 633 (1:200 Thermo Fisher
569 Scientific) for one hour at room temperature. Cells were washed twice with PBS and cover slips
570 mounted onto slides using mounting solution with DAPI for nuclear staining (ProLong Diamond Antifade
571 Mountant with DAPI, Life Technologies) overnight. Slides were imaged using Zeiss 710 confocal

572 microscope at 63x magnification and podosome analysis was carried out on at least 100 cells per sample
573 from 10 fields of view.

574 Filtering strategy for candidate regulatory compound heterozygotes

575 Being underpowered⁴² to detect single nucleotide variants affecting CREs, we limited our initial analysis
576 to large deletions overlapping exon, promoter or 'super-enhancer' CREs of known PID genes (**Extended**
577 **Data Fig. 4**). We selected uncommon (<0.03 frequency NIHR-RD BioResource cohort³⁸) large deletion
578 events (>50bp), occurring in PID index cases. We intersected these with a catalogue of cis-regulatory
579 elements linked to protein-coding genes, created by combining 'super-enhancer' and promoter (+/-
580 500bp window around any protein coding gene transcriptional start site) annotations with promoter
581 capture Hi-C data across 17 primary haematopoietic cell types²¹. Finally, we filtered these events so that
582 only those with linked genes, containing a potentially high impact (CADD>20) rare (MAF<0.001) coding
583 variant, within a previously reported pathogenic gene (IUIS 2017), were taken forward. Events
584 in *ARPC1B*, *LRBA* and *DOCK8* were functionally validated. The LRBA cHET variants were confirmed to be
585 in trans by sequencing the parents. Functional LRBA deficiency was demonstrated by impaired surface
586 CTLA-4 expression on Treg cells (**Extended Data Fig. 4**). In the absence of the patient's mother for
587 sequencing, the DOCK8 variants were confirmed to be in trans by nanopore sequencing and phasing of
588 merged long- and short-read data (see below and **Extended Data Fig. 5**). Functional DOCK8 deficiency
589 was confirmed by a typical clinical phenotype (severe immunodeficiency with prominent wart infection),
590 together with characteristic impaired ex-vivo CD8+, but preserved CD4+, T cell proliferation. The need
591 for rapid bone marrow transplantation has precluded further phenotypic analysis of this patient.

592 Phasing of DOCK8 variants

593 In order to confirm the phase of two variants detected in the *DOCK8* gene of a single individual, chr9:g.
594 306626-358548del and chr9:463519G>A, long read sequencing was performed using the Oxford
595 Nanopore Technologies PromethION platform. The DNA sample was prepared using the 1D ligation
596 library prep kit (SQK-LSK109), and genomic libraries were sequenced using a R.9.4.1 PromethION
597 flowcell. Raw signal data in FAST5 format was base called using Guppy (v2.3.5) to generate sequences in
598 FASTQ format, which were then aligned against the GRCh37/hg19 human reference genome using
599 minimap2 (v2.2). Average coverage was 14x and median read length was 4,558 ± 4,007. A high quality
600 set of heterozygous genotypes for the sample was created by using only variants from the short read
601 Illumina WGS data with a phred score of <20 (probability of correct genotype > 0.99). Haplotyping was
602 then performed with Whatshap (v0.14.1) by using the long Nanopore reads to bridge across the
603 informative genotypes from the short read data
604 (<https://whatshap.readthedocs.io/en/latest/index.html>). We obtained a single high confidence
605 haplotype block spanning the large deletion and the rare missense variant and showing that they were
606 in trans (**Extended data Fig. 5**).

607 AD-PID GWAS

608 GWAS was performed both on the whole PID cohort (N cases = 886) and on a subset comprising AD-PID
609 cases (N cases = 733); the results of the AD-PID analysis were less noisy, and had increased power to
610 detect statistical associations despite a reduced sample size (**Extended Data Fig. 6**). We used 9,225
611 unrelated samples from non-PID NBR-RD cohorts as controls.

612 Variants selected from a merged VCF file were filtered to include bi-allelic SNPs with overall MAF>=0.05
613 and minOPR=1 (100% pass rate across all WGS data for over 13,000 NBR participants). We ran PLINK
614 logistic association test under an additive model. We adjusted for read length to guard against technical
615 differences in genotype calls across the samples sequenced using 100bp, 125bp and 150bp reads, as
616 Illumina chemistries changed throughout the duration of the project. We also used sex and first 10
617 principal components from the ethnicity analysis as covariates, to mitigate against any population
618 stratification effects. After filtering out SNPs with HWE p<10⁻⁶, we were left with the total of 4,993,945

619 analysed SNPs. There was minimal genomic inflation of the test statistic ($\lambda = 1.022$), suggesting
620 population substructure and sample relatedness had been appropriately accounted for. Linear mixed
621 model (LMM) analysis, as implemented in the BOLT-LMM package⁴³, is an alternative method of
622 association testing correcting for population stratification. It was used to confirm the observed
623 associations (**Extended Data Table 3**). After genomic control correction⁴⁴ the only genome-wide
624 significant ($p < 5 \times 10^{-8}$) signal was at the MHC locus, with several suggestive ($p < 1 \times 10^{-5}$) signals (**Extended**
625 **Data Fig. 6**). We repeated the analysis with more relaxed SNP filtering criteria using $0.005 < \text{MAF} < 0.05$
626 and $\text{minOPR} > 0.95$ (**Extended Data Fig. 6**). The only additional signal identified were the three
627 *TNFRSF13B* variants shown in **Supplementary Note 3**.

628 We obtained summary statistics data from the Li et al. CVID Immunochip case-control study⁸ and, after
629 further genomic control correction ($\lambda = 1.039$), performed a fixed effects meta-analysis on 95,417
630 variants shared with our AD-PID GWAS. Genome-wide significant ($p < 5 \times 10^{-8}$) signals were seen at the
631 MHC and 16p13.13 loci, with several suggestive ($p < 1 \times 10^{-5}$) signals (**Extended Data Table 3**). After meta-
632 analysis, we conditioned on the lead SNP in each of the genome-wide and suggestive loci by including it
633 as an additional covariate in the logistic regression model in PLINK, to determine if the signal was driven
634 by single or multiple hits at those loci. The only suggestion of multiple independent signals was at the
635 MHC locus (**Extended Data Fig. 7**).

636 MHC locus analyses

637 We imputed classical HLA alleles using the method implemented in the SNP2HLA v1.0.3 package⁴⁵,
638 which uses Beagle v3.0.4 for imputation and the HapMap CEU reference panel. We imputed allele
639 dosages and best-guess genotypes of 2-digit and 4-digit classical HLA alleles, as well as amino acids of
640 the MHC locus genes *HLA-A*, *HLA-B*, *HLA-C*, *HLA-DRB1*, *HLA-DQA1* and *HLA-DQB1*. We tested the
641 association of both allele dosages and genotypes using the logistic regression implemented in PLINK,
642 and obtained similar results. We then used the best-guess genotypes to perform the conditional analysis
643 (see above), since conditioning is not implemented in PLINK in a model with allele dosages. We repeated
644 the conditional analyses as described above. The results of the sequential conditioning on the two lead
645 classical alleles and amino acids within the Class I and Class II regions are shown in **Extended Data Fig. 7**.

646 Allele Specific Expression

647 RNA and gDNA were extracted from PBMCs using the AllPrep kit (Qiagen) as per the manufacturer's
648 instructions. RNA was reverse transcribed to make cDNA using the SuperScriptTM VILOTM cDNA synthesis
649 kit with appropriate minus reverse transcriptase controls, as per the manufacturer's instructions. The
650 region of interest in the gDNA and 1:10 diluted cDNA was amplified using Phusion (Thermo Fisher) and
651 the following primers on a G-Storm thermal cycler with 30 seconds at 98°C then 35 cycles of 98°C 10
652 seconds, 60°C 30 seconds, 72°C 15 seconds.

653 **ARPC1B**

654 The region of interest spanning the frameshift variant was amplified using the following primers:
655 Forward: GGGTACATGGCGTCTGTTTC / Reverse: CACCAGGCTGTTGTCTGTGA

656 PCR products were run on a 3.5% agarose gel. Bands were cut out and product extracted using the QIA
657 Quick Gel Extraction Kit (Qiagen), as per protocol. Expected products were confirmed by Sanger
658 sequencing. 4ul fresh PCR product was used in a TOPO^o cloning reaction (Invitrogen) and used to
659 transform One ShotTM TOP10 chemically competent E. coli. These were cultured overnight then spread
660 on LB agar plates. Individual colonies were picked and genotyped. ARPC1B mRNA expression was
661 assessed using a Taqman gene expression assay with 18S and *EEF1A1* as control genes. Each sample was
662 run in triplicate for each gene with a no template control. PCR was run on a LightCycler[®] (Roche) with 2
663 mins 50°C, 20 seconds 95°C then 45 cycles of 95°C 3 seconds, 60°C 30 seconds.

664 **PTPN2**

665 PTPN2 ASE protocol is modified from above. RNA and genomic DNA were extracted from PBMCs using
666 the AllPrep Kit (Qiagen). RNA was treated with Turbo DNase (Thermo) and reverse transcribed to

667 generate cDNA using the SuperScript IV VILO master mix (Thermo). The intronic region of interest in
668 gDNA and cDNA was amplified by two nested PCR reactions using Phusion enzyme (Thermo). The
669 primers (F1/R1) and nested primers (F2/R2) used were:

670 Forward_1: aaagtctggagcaggcagag / Reverse_1: tgggggaactggttatgctttc

671 Forward_2: ggagctatgatcacgccacatg / Reverse_2: atgctttctggttgggctgac

672 PCR products were run on a 1% agarose gel. Bands were cut out and product extracted using the QIA
673 Quick Gel Extraction Kit (Qiagen), as per protocol. Expected products were confirmed by Sanger
674 sequencing. 5ng fresh PCR product was used in a TOPO[®]cloning reaction (Invitrogen) and used to
675 transform One Shot™ TOP10 chemically competent E. coli. These were cultured overnight then spread
676 on LB agar plates. Individual colonies were picked and genotyped. PTPN2 mRNA expression was
677 assessed using a Taqman SNP genotyping assay and on a LightCycler (Roche).

678 PAGE and Western Blot analysis

679 Samples were separated by SDS polyacrylamide gel electrophoresis and transferred onto a nitrocellulose
680 membrane. Individual proteins were detected with antibodies p-STAT1, against STAT1, against SOCS1,
681 against PTPN2 (Cell Signaling Technology, Inc. 3 Trask Lane, Danvers, MA 01923, USA), against ARPC1b
682 (goat polyclonal antibodies, ThermoScientific, Rockford, IL, USA), against ARPC1a (rabbit polyclonal
683 antibodies, Sigma, St Louis, USA) and against actin (mouse monoclonal antibody, Sigma). Secondary
684 antibodies were either donkey-anti-goat-IgG IRDye 800CW, Goat-anti-mouse-IgG IRDye 800CW or
685 Donkey-anti-rabbit-IgG IRDye 680CW (LI-COR Biosciences, Lincoln, NE, USA). Quantification of bound
686 antibodies was performed on an Odyssey Infrared Imaging system (LI-COR Biosciences, Lincoln, NE,
687 USA). Specifically, for IVNS1ABP, whole cell lysates of peripheral blood mononuclear cells were lysed on
688 ice with LDS NuPAGE (Invitrogen) at a concentration of 10⁵ cells per 15ul of LDS. Lysates were denatured
689 at 70°C for 10 minutes then cooled. Lysates were loaded run on Bis-Tris 4-12% Protein Gels (Invitrogen)
690 then transferred to a PVDF membrane (Invitrogen) using iBlot 2 Dry Blotting System (Thermo Fisher
691 Scientific). Membranes were blocked with 5% milk in 5% tris-buffered saline with 0.01% Tween-20
692 (TBST) for 1 hour at room temperature then incubated overnight with the primary antibodies anti-
693 GAPDH (Cell Signaling Technology) and anti-IVNS1ABP (Atlas Antibodies). Membranes were then
694 washed 3x with TBST at room temperature then incubated with secondary anti-rabbit HRP-conjugated
695 antibody (Cell Signaling Technology) for 1 hour. Membranes were then washed 3x with TBST and 1x with
696 phosphate buffered saline. Membranes were then exposed with Pierce ECL Western Blotting Substrate
697 (Thermo Fischer Scientific) and developed with CL-XPosure Film (Thermo Fischer Scientific).

698 Flow cytometry

699 Peripheral blood mononuclear cells were prepared for analysis by density centrifugation using
700 Histopaque-1077 (Sigma-Aldrich). The following antibodies were used for flow cytometry
701 immunophenotyping: CD3 – BV605 (Biolegend, San Diego, CA, USA), CD4 – APC-eFluor780 (eBioscience,
702 San Diego, CA, USA), CD8 – BV650 (eBioscience, San Diego, CA, USA), CD25 – PE (eBioscience, San Diego,
703 CA, USA), CD127 – APC (eBioscience, San Diego, CA, USA), CD45RA – PerCP-Cy5.5 (eBioscience, San Diego,
704 CA, USA), CD19 – BV450 (BD Bioscience, Franklin Lakes, NJ, USA), CD27 – PE-Cy7 (eBioscience, San Diego,
705 CA, USA), CD62L – APC-eF780 (eBioscience, San Diego, CA, USA), CXCR3 – FITC (Biolegend, San Diego, CA,
706 USA), CXCR5 – AF488 (Biolegend, San Diego, CA, USA), CCR7 – PE (Biolegend, San Diego, CA, USA), PD-1
707 – APC (eBioscience, San Diego, CA, USA), HLA-DR- eFluor450 (eBioscience, San Diego, CA, USA), IgD –
708 FITC (BD Bioscience, Franklin Lakes, NJ, USA). Flow cytometry analysis was performed on a BD
709 LSRFortessa (BD Bioscience) with FACS Diva software (BD Bioscience) for acquisition, then analysis was
710 performed with FlowJo software (LLC).

711 AD-PID GWAS Enrichment

712 Due to the size of the AD-PID cohort, we were unable to use LD-score regression⁴⁶ to assess genetic
713 correlation between distinct and related traits. We therefore adapted the previous enrichment method

714 `blockshifter`⁴⁷ in order to assess evidence for the enrichment of AD-PID association signals in a
715 compendium of 9 GWAS European Ancestry summary statistics was assembled from publicly available
716 data. We removed the MHC region from all downstream analysis [GRCh37 chr6:25-45Mb]. To adjust for
717 linkage disequilibrium (LD), we split the genome into 1cM recombination blocks based on HapMap
718 recombination frequencies⁴⁸. For a given GWAS trait, for n variants within LD block b we used
719 Wakefield's synthesis of asymptotic Bayes factors (aBF)⁴⁹ to compute the posterior probability that the
720 i^{th} variant is causal ($PPCV_i$) under single causal variant assumptions⁵⁰:

$$PPCV_i = \frac{aBF_i \pi_i}{\sum_{j=1}^n (aBF_j \pi_j) + 1}$$

721 Here $\pi_i = \pi_j$ are flat prior probabilities for a randomly selected variant from the genome to be causal
722 and we use the value $1 \times 10^{-4.51}$. We sum over these PPCV within an LD block, b to obtain the posterior
723 probability that b contains a single causal variant (PPCB).

724 To compute enrichment for trait t , we convert PPCBs into a binary label by applying a threshold such
725 that $PPCB_t > 0.95$. We apply these block labels for trait t , to PPCBs (computed as described above) for
726 our AD-PID cohort GWAS, using them to compute a non-parametric Wilcoxon rank sum statistic, W
727 representing the enrichment. Whilst the aBF approach naturally adjusts for LD within a block, residual
728 LD between blocks may exist. In order to adjust for this and other confounders (e.g. block size) we use a
729 circularised permutation technique⁵² to compute W_{null} . To do this, for a given chromosome, we select
730 recombination blocks, and circularise such that beginning of the first block adjoins the end of the last.
731 Permutation proceeds by rotating the block labels, but maintaining AD-PID PPCB assignment. In this way
732 many permutations of W_{null} can be computed whilst conserving the overall block structure.

733 For each trait we used 10^4 permutations to compute adjusted Wilcoxon rank sum scores using *wgsea*
734 [<https://github.com/chr1swallace/wgsea>] R package. For detailed method description see
735 **Supplementary Note 4.**

736 PID monogenic candidate gene prioritisation

737 We hypothesised, given the genetic overlap with antibody associated PID, that common regulatory
738 variation, elucidated through association studies of immune-mediated disease, might prioritise genes
739 harbouring damaging LOF variants underlying PID. Firstly, using summary statistics from our combined
740 fixed effect meta-analysis of AD-PID, we compiled a list of densely genotyped ImmunoChip regions
741 containing one or more variant where $P < 1 \times 10^{-5}$. Next, we downloaded ImmunoChip (IC) summary
742 statistics from ImmunoBase (accessed 30/07/2018) for all 11 available studies. For each study we
743 intersected PID suggestive regions, and used COGS (<https://github.com/ollyburren/rCOGS>) in
744 conjunction with promoter-capture Hi-C datasets for 17 primary cell lines^{21,47} in order to prioritise genes.
745 We filtered by COGS score to select protein coding genes with a COGS score > 0.5 , obtaining a list of 11
746 protein coding genes out of a total of 54 considered.

747 We further hypothesised that genes harbouring rare LOF variation causal for PID would be intolerant to
748 variation. We thus downloaded pLI scores⁵³ and took the product between these and the COGS scores
749 to compute an `overall' prioritisation score across each trait and gene combination. We applied a final
750 filter taking forward only those genes having an above average `overall' score to obtain a final list of 6
751 candidate genes (Fig. 4d). Finally, we filtered the cohort for damaging rare (gnomAD AF < 0.001) protein-
752 truncating variants (frameshift, splice-site, nonsense) within these genes in order to identify individuals
753 for functional follow up.

754 Statistical analyses

755 Statistical analyses were carried out using R (v3.3.3 – "Another Canoe") and Graphpad Prism (v7) unless
756 otherwise stated. All common statistical tests are two-sided unless otherwise stated. No statistical
757 methods were used to pre-determine sample size

758

759 **Methods References**

760

- 761 38. The NIHR BioResource. Whole-genome sequencing of rare disease patients in a national
762 healthcare system. *bioRxiv* 507244 (2019) doi:10.1101/507244.
- 763 39. Carss, K. J. *et al.* Comprehensive Rare Variant Analysis via Whole-Genome Sequencing to
764 Determine the Molecular Pathology of Inherited Retinal Disease. *Am. J. Hum. Genet.* **100**, 75–90
765 (2017).
- 766 40. McLaren, W. *et al.* The Ensembl Variant Effect Predictor. *Genome Biol.* **17**, 122 (2016).
- 767 41. Mathieson, I. & McVean, G. Differential confounding of rare and common variants in spatially
768 structured populations. *Nat. Genet.* **44**, 243–246 (2012).
- 769 42. Short, P. J. *et al.* De novo mutations in regulatory elements in neurodevelopmental disorders.
770 *Nature* **555**, 611–616 (2018).
- 771 43. Loh, P.-R. *et al.* Efficient Bayesian mixed-model analysis increases association power in large
772 cohorts. *Nat. Genet.* **47**, 284 (2015).
- 773 44. Devlin, B. & Roeder, K. Genomic Control for Association Studies. *Biometrics* **55**, 997–1004 (1999).
- 774 45. Jia, X. *et al.* Imputing amino acid polymorphisms in human leukocyte antigens. *PLoS One* **8**,
775 e64683 (2013).
- 776 46. Bulik-Sullivan, B. K. *et al.* LD Score regression distinguishes confounding from polygenicity in
777 genome-wide association studies. *Nat. Genet.* **47**, 291–5 (2015).
- 778 47. Burren, O. S. *et al.* Chromosome contacts in activated T cells identify autoimmune disease
779 candidate genes. *Genome Biol.* **18**, 165 (2017).
- 780 48. The International HapMap Consortium *et al.* A second generation human haplotype map of over
781 3.1 million SNPs. *Nature* **449**, 851–61 (2007).
- 782 49. Wakefield, J. Bayes factors for genome-wide association studies: comparison with *P*-values.
783 *Genet. Epidemiol.* **33**, 79–86 (2009).
- 784 50. Wellcome Trust Case Control Consortium, J. B. *et al.* Bayesian refinement of association signals
785 for 14 loci in 3 common diseases. *Nat. Genet.* **44**, 1294–301 (2012).
- 786 51. Huang, H. *et al.* Fine-mapping inflammatory bowel disease loci to single-variant resolution.
787 *Nature* **547**, 173–178 (2017).
- 788 52. Trynka, G. *et al.* Disentangling the Effects of Colocalizing Genomic Annotations to Functionally
789 Prioritize Non-coding Variants within Complex-Trait Loci. *Am. J. Hum. Genet.* **97**, 139–52 (2015).
- 790 53. Lek, M. *et al.* Analysis of protein-coding genetic variation in 60,706 humans. *Nature* **536**, 285–91
791 (2016).

792

793 Acknowledgements: Funding for the NIHR-BioResource was provided by the National Institute for Health
794 Research (NIHR, grant number RG65966). We gratefully acknowledge the participation of all NIHR
795 BioResource volunteers, and thank the NIHR BioResource centre and staff for their contribution. JEDT is
796 supported by the MRC (RG95376 and MR/L006197/1). AJT is supported by the Wellcome Trust
797 (104807/Z/14/Z) and the NIHR Biomedical Research Centre at Great Ormond Street Hospital for Children
798 NHS Foundation Trust and University College London. KGCS is supported by the Medical Research
799 Council (program grant MR/L019027) and is a Wellcome Investigator. AJC was supported by the
800 Wellcome [091157/Z/10/Z], [107212/Z/15/Z], [100140/Z/12/Z], [203141/Z/16/Z]; JDRF [9-2011-253], [5-
801 SRA-2015-130-A-N]; NIHR Oxford Biomedical Research Centre and the NIHR Cambridge Biomedical
802 Research Centre. EE has received funding from the European Union Seventh Framework Programme
803 (FP7-PEOPLE-2013-COFUND) under grant agreement no 609020- Scientia Fellows. ER is supported
804 supported by the Wellcome Trust [201250/Z/16/Z]. DE is supported by the German Federal Ministry of
805 Education and Research (BMBF) within the framework of the e:Med research and funding
806 concept (SysInflame grant 01ZX1306A; GB-XMAP grant 01ZX1709) and funded by the Deutsche
807 Forschungsgemeinschaft (DFG, German Research Foundation) under Germany's Excellence Strategy –
808 EXC 2167-390884018.

809
810

811 Author Contributions: JEDT, ES, JS, ZZ, WR, NSG, PT, ER, AJC carried out experiments. HLA, OSB, JEDT,
812 JHRF, DG, IS, CP, SVVD, ASJ, JM, JS, PAL, AGL, KM, EE, DE, SFJ, THK, ET performed computational analysis
813 of the data. HLA, IS, CP, MB, CrS, RL, PJRM, JS, KES conducted sample and data processing. JEDT, ES, WR,
814 MJT, RBS, PG, HEB, AW, SH, RL, MSB, KCG, DSK, AC, DE, AH, NC, SG, AH, SG, SJ, CaS, FB, SS, SOB, TWK,
815 WHO, AJT recruited patients, provided clinical phenotype data and confirmed genetic diagnosis. All
816 authors contributed to the analysis of the presented results. KGCS, JEDT, HLA, WR and OSB wrote the
817 paper with input from all other authors. KGCS, WHO, AJT and TWK conceived and oversaw the research
818 programme.

819
820

821 **Author Information**

822

823 Members of the NBR-RD PID Consortium: Zoe Adhya, Hana Alachkar, Carl E Allen, Ariharan
824 Anantharachagan, Richard Antrobus, Gururaj Arumugakani, Chiara Bacchelli, Helen E Baxendale, Claire
825 Bethune, Shahnaz Bibi, Barbara Boardman, Claire Booth, Matthew Brown, Michael J Browning, Mary
826 Brownlie, Matthew S Buckland, Siobhan O Burns, Oliver S Burren, Anita Chandra, Ivan K. Chinn, Hayley
827 Clifford, Nichola Cooper, Godelieve J de Bree, E Graham Davies, Sarah Deacock, John Dempster, Lisa A
828 Devlin, Elizabeth Drewe, J David M Edgar, William Egner, Shuayb El Khalifa, Tariq El-Shanawany, James H
829 R Farmery, H Bobby Gaspar, Rohit Ghurye, Kimberly C Gilmour, Sarah Goddard, Pavels Gordins, Sofia
830 Grigoriadou, Scott J Hackett, Rosie Hague, Lorraine Harper, Grant Hayman, Archana Herwadkar, Stephen
831 Hughes, Aarnoud P Huissoon, Stephen Jolles, Julie Jones, Yousuf M Karim, Peter Kelleher, Sorena Kiani,
832 Nigel Klein, Taco W Kuijpers, Dinakantha S Kumararatne, James Laffan, Hana Lango Allen, Sara E Lear,
833 Hilary Longhurst, Lorena E Lorenzo, Paul A Lyons, Jesmeen Maimaris, Ania Manson, Elizabeth M
834 McDermott, Hazel Millar, Anoop Mistry, Valerie Morrisson, Sai H K Murng, Iman Nasir, Sergey Nejentsev,
835 Sadia Noorani, Eric Oksenhendler, Mark J Ponsford, Waseem Qasim, Ellen Quinn, Isabella Quinti, Alex
836 Richter, Crina Samarghitean, Ravishankar B Sargur, Sinisa Savic, Suranjith L Seneviratne, W A Carrock
837 Sewell, Fiona Shackley, Olga Shamardina, Ilenia Simeoni, Kenneth G C Smith, Emily Staples, Hans Stauss,
838 Cathal L Steele, James E Thaventhiran, David C Thomas, Moira J Thomas, Adrian J Thrasher, John A Todd,
839 Anton T J Tool, Salih Tuna, Rafal D Urniaz, Steven B Welch, Lisa Willcocks, Sarita Workman, Austen
840 Worth, Nigel Yeatman, Patrick F K Yong.

841
842 Reprints and permissions information is available at www.nature.com/reprints. Readers are welcome to
843 comment on the online version of the paper.

844
845 Competing interests

846 The authors declare no competing financial interests.

847
848 Corresponding Authors

849 Correspondence and requests for materials should be addressed to J.E.D.T. (jedt2@cam.ac.uk) and
850 K.G.C.S. (kgcs2@cam.ac.uk)

851
852 **Ethics Declaration**

853 NBR-RD participants from the UK were consented under the East of England Cambridge South national
854 research ethics committee (REC) reference 13/EE/0325. Participants recruited outside of the UK were
855 consented by the recruiting clinicians under the ethics governance of their respective hospitals.

856
857 **Data Availability**

858 WGS and phenotype data from participants is available from one of 3 data repositories determined by
859 the informed consent of the participant. (1) Data from participants enrolled in the NIHR BioResource for
860 the 100,000 Genomes Project–Rare Diseases Pilot can be accessed via Genomics England Limited:
861 <https://www.genomicsengland.co.uk/about-gecip/joining-research-community/>. (2) data from the UK
862 Biobank samples are available through a data release process overseen by UK Biobank
863 (<https://www.ukbiobank.ac.uk/>). (3) data from the remaining NIHR BioResource participants is available
864 from the European Genome-phenome Archive (EGA) at the EMBL European Bioinformatics Institute
865 (EGA accession code EGAD00001004523). Patients all fall into group (3) and controls into groups (1)-(3).
866 Variants listed in Supplementary Table 1 (diagnostic findings) have been submitted to ClinVar and are
867 accessible under “NIHR_Bioresource_Rare_Diseases_PID”. Summary statistics are available via GWAS
868 Catalog [Accession number granted upon acceptance of the manuscript].

869
870 **Code Availability**

871 R code for running major analyses are available at
872 https://github.com/ollyburren/pid_thaventhiran_et_al.

873
874 **Extended Data Figures and Tables**

875 **Extended Data Figure 1 – Graphical abstract**

876 **Extended Data Figure 2 – Genetic testing in the PID cohort prior to WGS recruitment, in sporadic**
877 **versus familial cases.** Any type of genetic test is included, such as single exon/gene sequencing, MLPA,
878 or targeted gene panel/exome sequencing. The information was supplied on the referral form and is
879 likely an underestimate of the number of patients with additional genetic testing.

880 **Extended Data Figure 3 – BeviMed simulation study of Positive Predictive Value (PPV) with increasing**
881 **disease cohort size.** We simulated genotypes at 25 rare variant sites in a hypothetical locus amongst
882 20,000 controls and a further 1,000, 2,000, 3,000, 4,000 or 5,000 cases. We simulated that 0.2%, 0.3%,
883 0.4% or 0.5% of the cases had the hypothetical locus as their causal locus. We distinguish between cases

884 due to the hypothetical locus (CHLs) and cases due to other loci (COLs). The allele frequency of 20
885 variants was set to 1/10,000 amongst the cases and COLs. The allele frequency of the remaining 5
886 variants was set to zero amongst the controls and COLs. One of the five variants was assigned a
887 heterozygous genotype amongst the CTLs at random. Thus, we represent a dominant disorder caused by
888 variants with full penetrance. As inference is typically performed across thousands of loci, with only a
889 small number being causal, we assumed a mixture of 100 to 1 non-causal to causal loci. In order to
890 compute the PPV for a given threshold on the posterior probability of association (PPA), we computed
891 PPAs for 10,000 datasets without permutation of the case/control labels and 10,000 further datasets
892 with a permutation of the case/control labels. We then sampled 1,000 PPAs from the permuted set and
893 10 PPAs from the non-permuted set to compute the PPV obtained when the PP threshold was set to
894 achieve 100% power. The mean over 2,000 repetitions of this procedure is shown on the y-axis. The x-
895 axis shows the number of cases in a hypothetical cohort. As the number of cases increases from 1,000 to
896 5,000, the PPV increases above 87.5% irrespective of the proportion of cases with the same genetic
897 aetiology. This demonstrates the utility of expanding the size of the PID case collection for detecting
898 even very rare aetiologies resulting in the same broad phenotype as cases with different aetiologies. In
899 practice, the PPV/power relationship may be much better, as the wealth of phenotypic information of
900 the cases can allow subcategorization of cases to better approximate shared genetic aetiologies.

901 **Extended Data Figure 4 – Candidate cHET filtering strategy and LRBA patient. (a)** Filtering strategy to
902 identify candidate compound heterozygous (cHET) pathogenic variants consisting of a rare coding
903 variant in a PID-associated gene and a deletion of a cis-regulatory element for the same gene. **(b)**
904 Regional plot of the compound heterozygous variants. Gene annotations for are taken from Ensembl
905 Version 75, and the transcripts shown are those with mRNA identifiers in RefSeq (ENST00000357115
906 and ENST00000510413). The position of each variant relative to the gene transcript is shown by a red
907 bar, with the longer bar indicating the extent of the deleted region. Variant coordinates are shown for
908 the GRCh37 genome build. **(c)** Pedigree of LRBA patient demonstrating phase of the causal variants. **(d)**
909 FACS dotplot of CTLA-4 and FoxP3 expression in LRBA cHET patient and a healthy control (representative
910 of 2 independent experiments). Numbers in black are the percentage in each quadrant. Numbers in red
911 are the MFI of CTLA-4 staining in FoxP3 -ve and FoxP3 +ve cells. **(e)** Normalised CTLA-4 expression,
912 assessed as previously described in Hou *et al.* (Blood, 2017), in the LRBA cHET patient (n=1), healthy
913 controls (n=8) and positive control CTLA-4 (n=4) and LRBA (n=3 deficient patients. Horizontal bars
914 indicate mean +/- SEM.

915 **Extended Data Figure 5 - DOCK8 cHET patient. (a)** Regional plot of the compound heterozygous
916 variants. Gene annotations for are taken from Ensembl Version 75, and the transcripts shown are those
917 with mRNA identifiers in RefSeq (ENST00000432829 and ENST00000469391). The position of each
918 variant relative to the gene transcript is shown by a red bar, with the longer bar indicating the extent of
919 the deleted region. Variant coordinates are shown for the GRCh37 genome build. **(b)** Photographs of the
920 extensive HPV associated wart infection in the *DOCK8* cHET patient. **(c)** cHET variant phasing. Top:
921 cartoon representation of phasing using high quality heterozygous calls from short read WGS data and
922 long-read nanopore sequencing data. Bottom panel: WGS and nanopore data from the *DOCK8* patient.
923 The two variants (large deletion and missense substitution) are shown in the bottom track (orange), and
924 a single phase block (green) that spans the entire region between the two variants confirmed them to
925 be in-trans. **(d)** Dye-dilution proliferation assessment in response to phytohaemagglutinin (PHA) and
926 anti-CD3/28 beads in CD4+ and CD8+ T cells in patient and control cells (representative of 2 independent
927 experiments). Staining was performed with CFSE dye (Invitrogen, Carlsbad, CA, USA) with the same
928 additional fluorochrome markers as described in the flow cytometry methods section.

929 **Extended Data Figure 6 – Manhattan plots of (a) all-PID MAF>5%, (b) AD-PID MAF>5% and (c) AD-PID**
930 **0.5%<MAF<5% GWAS results.** Sample sizes: all-PID cases n=886; AD-PID cases n=733; controls n=9,225.

931 Each point represents an individual SNP association P-value, adjusted for genomic inflation. Only signals
932 with $P < 1 \times 10^{-2}$ are shown. None of the SNPs in plot (c) appear in the results of the common variant
933 GWAS in (b), and are therefore additional signals gained from a GWAS including variants of
934 intermediate MAF. Red and blue lines represent genome-wide ($P < 5 \times 10^{-8}$) and suggestive ($P < 1 \times 10^{-5}$)
935 associations, respectively. Note the additional genome-wide significant signal representing the
936 *TNFRSF13B* locus, and several suggestive associations that only become apparent with variants in the
937 0.5% - 5% MAF range shown in (c). Suggestive loci are indicated by the rsID of the lead SNP in each
938 chromosome. Note that lead SNPs in AD-PID GWAS (b) may differ from meta-analysis lead SNPs.

939 **Extended Data Figure 7 – MHC locus conditional analyses in AD-PID GWAS (cases n=733, controls**
940 **n=9,225).** (a) Locuszoom association plots of AD-PID GWAS MHC locus initial (top) and conditional
941 (middle, bottom) analyses results. The x and left y axes represent the chromosomal position and the -
942 log10 of the association P-value, respectively. Each point represents an analysed SNP, with the lead SNP
943 indicated by a purple diamond and all other points coloured according to the strength of their LD with
944 the lead SNP. Purple lines represent HapMap CEU population recombination hotspots. The bottom
945 panel shows a selection of genes in the region, with over 150 genes omitted. Top: association plot of the
946 most significant signal rs1265053, which is in the Class I region and close to *HLA-B* and *HLA-C* genes.
947 Middle: plot showing the association remaining upon conditioning on rs1265053, with the strongest
948 signal rs9273841 mapping to the Class II region close to *HLA-DRB1* and *HLA-DQA1* genes. Bottom: plot
949 showing the association signal remaining upon conditioning on both rs1265053 and rs9273841. (b,c)
950 MHC locus conditional analyses of the classical HLA alleles (b) and amino acids of individual HLA genes
951 (c). Each point represents a single imputed classical allele or amino acid, with those marked in red
952 indicating those added as covariates to the logistic regression model: the Class I signal (second row
953 plots), the Class II signal (third row plots), and both Class I and Class II signals (bottom row plots). The
954 HLA allele and amino acid shown in the bottom plots are those with the lowest P-value remaining after
955 conditioning on both Class I and Class II signals; as there are no genome-wide significant signals
956 remaining, the results suggest there are two independent signals at the MHC locus. (d) Protein
957 modelling of two independent MHC locus signals: *HLA-DRB1* residue E71 and *HLA-B* residue N114 using
958 PDB 1BX2 and PDB 4QRQ respectively. Protein is depicted in white, highlighted residue in red, and
959 peptide is in green.

960 **Extended Data Table 1 – ESID definition of PID subtypes.** Participants were defined phenotypically to
961 the groups: primary antibody deficiency, CVID, CID, severe autoimmunity/immune dysregulation,
962 autoinflammatory syndrome, phagocyte disorder, and unspecified PID according to the European
963 Society for Immunodeficiencies (ESID) registry diagnostic criteria ([https://esid.org/Working-](https://esid.org/Working-Parties/Registry-Working-Party/Diagnosis-criteria)
964 [Parties/Registry-Working-Party/Diagnosis-criteria](https://esid.org/Working-Parties/Registry-Working-Party/Diagnosis-criteria)).

965 **Extended Data Table 2 – Description of the NIHR BioResource - Primary Immunodeficiency cohort.**
966 High-level clinical description and relevant clinical features were provided by recruiting clinicians. Index
967 cases are patients recruited as sporadic cases or probands in pedigrees, and determined to be
968 genetically unrelated by pairwise comparisons of common SNP genotypes in the WGS data. Numbers in
969 brackets refer to the percentage of index cases in each category. Total number of patients is the sum of
970 index cases and any affected relatives sequenced in this study.

971 **Extended Data Table 3 – Genome-wide significant ($P < 5 \times 10^{-8}$) and suggestive ($P < 1 \times 10^{-5}$) signals in our**
972 **AD-PID and Li *et al.* (Nat Comm, 2015) CVID GWAS meta-analysis.** The AD-PID WGS cohort included 733
973 cases and 9225 controls, whereas the CVID ImmunoChip cohort included 778 cases and 10999 controls.
974 The total number of shared meta-analysed variants was 95417. P-values are adjusted for individual
975 study genomic inflation factor lambda. The selection of genes from each locus used in COGS analysis is
976 described in Methods and Supplementary Note 3.







